



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 9/127</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/26250</b> <b>(43) International Publication Date:</b> 24 November 1994 (24.11.94)
<b>(21) International Application Number:</b> PCT/US93/04645 <b>(22) International Filing Date:</b> 14 May 1993 (14.05.93) <b>(71) Applicant:</b> DEPOTECH CORPORATION [US/US]; 11025 North Torrey Pines Road, La Jolla, CA 92037 (US). <b>(72) Inventors:</b> KIM, Sinil; 548 Ford Avenue, Solano Beach, CA 92075 (US). HOWELL, Stephen, B.; 13612 Nogales Drive, Del Mar, CA 92014 (US). <b>(74) Agents:</b> WETHERELL, John, R., Jr. et al.; Spensley Horn Jubas & Lubitz, Suite 500, 1880 Century Park East, Los Angeles, CA 90067 (US).		<b>(81) Designated States:</b> CA, JP.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD FOR TREATING NEUROLOGICAL DISORDERS		
<b>(57) Abstract</b>  A method for ameliorating a neurological disorder in a human by administration to the cerebrospinal fluid (CSF) of a therapeutic agent in a dispersion system which allows the therapeutic agent to persist in the cerebro-ventricular space.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

**METHOD FOR TREATING NEUROLOGICAL DISORDERS****BACKGROUND OF THE INVENTION****1. *Field of the Invention***

5 The present invention relates to a method for treating a neurological disorder using a slow-release vehicle for delivery of a therapeutic agent to the cerebrospinal (CSF) of a human.

**2. *Description of the Related Art***

10 Neurological disorders are among the most difficult diseases to treat. A major complicating factor in treating such disorders is the inability of many drugs to penetrate the blood-brain barrier when the agent is administered systemically. This ineffectiveness of classical drug delivery to address this need is particularly problematic with respect to chronic neurological disorders, such as those caused by benign or malignant cell proliferation or various viral etiologic agents.

15 Among the most difficult chronic neurological disorders to treat are those derived from metastatic infiltration, such as neoplastic meningitis. Neoplastic meningitis results from the metastatic infiltration of the leptomeninges by cancer, and is most commonly a complication of acute leukemia, lymphoma, or carcinoma of the breast and lung. Autopsy studies indicate that 5 to 8  
20 percent of solid tumor patients develop metastasis to the leptomeninges during the course of disease. Evidence suggests that the incidence of neoplastic meningitis may be increasing, in part due to increased survival from effective systemic therapies. (Bleyer, *Curr. Probl. Cancer*, 12:184, 1988).

-2-

Standard treatment for neoplastic meningitis includes single agent or combination intrathecal chemotherapy and radiation therapy. Radiotherapy to the entire neuraxis often produces severe marrow depression and has not been satisfactory in controlling active leptomeningeal disease except in leukemic meningitis. (Kogan, in *Principle and Practice of Radiation Oncology*, Perez, et al. eds., Lippincott, Philadelphia, PA, pp. 1280-1281, 1987). Systemic chemotherapy likewise is not generally effective in active meningeal malignancy because of poor drug penetration through the blood-brain barrier. (Blasberg, et al., *Can. Treat. Rep.*, 61:633, 1977; Shapiro, et al., *New Eng. J. Med.*, 293:161, 1975). Cytarabine, one of the three chemotherapeutic agents most commonly used for intrathecal therapy of neoplastic meningitis, is a cell-cycle phase specific agent that kills cells only when DNA is being synthesized. Consequently, optimal tumor kill with agents such as cytarabine requires constant infusion or frequent daily injections to maintain therapeutic concentrations for extended periods in CSF. This procedure is uncomfortable for patients, time consuming for physicians, and associated with an increased risk of infectious meningitis. Therefore, there is a need for a slow-releasing depot formulation which can allow a therapeutic agent to persist in contact with a neurological disorder in order to achieve an ameliorative effect. The present invention addresses this need.

**SUMMARY OF THE INVENTION**

The present invention arose from the seminal discovery that the clinical effectiveness of therapeutic agents in the treatment of neurological disorders in humans could be greatly enhanced if the therapeutic agent was administered as part of a dispersion system. This therapeutic approach allows effective dose levels of the agent to be maintained over a relatively long period of time such that the neurological disorder is continuously exposed to the agent. Surprisingly, the dispersion system containing the therapeutic agent can be effectively administered intralumbar even though the primary foci of the neurological disorder are centered in the cranium region, such as the ventricles.

**BRIEF DESCRIPTION OF THE DRAWINGS**

FIGURE shows the ventricular CSF pharmacokinetics of intraventricularly administered DTC 101 as a function of dose from 12.5 to 125 mg.

5      FIGURE 2 shows the maximum CSF cytarabine concentration [Panel A] and AUC [Panel B] as functions of dose.

FIGURE 3 shows a comparison of the ventricular (closed circles) and lumbar (open circles) cytarabine concentrations [total and free, Panels A and B, respectively] and DTC 101 particle count [Panel C] as functions of time following intraventricular administration of DTC 101.

10      FIGURE 4 shows cytarabine concentration in the ventricular CSF as a function of time (solid lines), and lumbar CSF cytarabine concentration at 3 minutes and 14 days (broken lines), following intralumbar administration of DTC 101.

**DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

The present invention is directed to a method for ameliorating neurological disorders which comprises administering a therapeutic agent to the cerebral spinal fluid (CSF). The surprising ability of the therapeutic agent to ameliorate the neurological disorder is due to the presentation of the therapeutic agent in a dispersion system which allows the agent to persist in the cerebro-ventricular space. The ability of the method of the invention to allow the therapeutic agent to persist in the region of the neurological disorder provides a particularly effective means for treating those disorders which are chronic and, thereby, are particularly difficult to achieve a clinical effect.

The term "neurological disorder" denotes any disorder which is present in the brain, spinal column, and related tissues, such as the meninges, which are responsive to an appropriate therapeutic agent. Among the various neurological disorders for which the method of the invention is effective are those which relate to a cell proliferative disease. The term "cell proliferative disease" embraces malignant as well as non-malignant cell populations which often appear morphologically to differ from the surrounding tissue. Thus, the cell proliferative disease may be due to a benign or a malignant tumor. In the latter instance, malignant tumors may be further characterized as being primary tumors or metastatic tumors, that is, tumors which have spread from systemic sites. Primary tumors can arise from glial cells (astrocytoma, oligodendroglioma, glioblastoma), ependymal cells (ependymoma) and supporting tissue (meningioma, schwannoma, papilloma of the choroid plexus). In children, tumors typically arise from more primitive cells (medulloblastoma, neuroblastoma, chordoma), whereas in adults astrocytoma and glioblastoma are the most common. However, the most common CNS tumors in general

-6-

are metastatic, particularly those which infiltrate the leptomeninges. Tumors that commonly metastatically invade the meninges include non-Hodgkin's lymphoma, leukemia, melanoma, and adenocarcinoma of breast, lung, or gastrointestinal origin.

- 5 The method of the invention is also useful in ameliorating neurological disorders which arise as a result of an infectious disease. Aseptic meningitis and encephalitis are CNS diseases which are caused by a virus. Among the viral infections which may benefit most from the ability of the method of the invention to allow the therapeutic agent to persist are those viral diseases  
10 caused by a slow virus or a retrovirus. Of particular interest among the retroviruses are the *Lentivirus*, which include HTLV-I, HTLV-II, HIV-1 and HIV-2.

- Neurological disorders which arise due to an infectious disease caused by a prokaryote can also be treated according to the method of the invention. Typically, the procaryotic etiologic agent is a bacteria such as *Hemophilus*  
15 *influenzae*, *Neisseria meningitidis*, *Streptococcus pneumonia*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella-Enterobacter*, *Proteus*, *Mycobacterium tuberculosis*, *Staphylococcus aureus*, and *Listeria monocytogenes*. Alternatively, the infectious disease can be caused by a eukaryote, such as a fungus. Important fungi which can be treated according to the method  
20 invention include *Cryptococcus*, *Coccidioides immitis*, *Histoplasma*, *Candida*, *Nocardia*, and *Blastomyces*.

- The therapeutic agents used according to the method of the invention are administered to the CSF in a delivery system such as synthetic or natural polymers in the form of macromolecular complexes, nanocapsules,  
25 microspheres, or beads, and lipid-based systems including oil-in-water



-7-

emulsions, micelles, mixed micelles, synthetic membrane vesicles, and resealed erythrocytes. These systems are known collectively as dispersion systems. Typically, the particles comprising the system are about 20 nm - 50  $\mu$ m in diameter. The size of the particles allows them to be suspended in a pharmaceutical buffer and introduced to the CSF using a syringe. The administration may be intraventricularly or, more preferably, intrathecally. Most preferred is injection of the particles by intralumbar puncture.

Materials used in the preparation of dispersion systems are typically sterilizable via filter sterilization, nontoxic, and biodegradable, for example, albumin, ethylcellulose, casein, gelatin, lecithin, phospholipids, and soybean oil can be used in this manner. Polymeric dispersion systems can be prepared by a process similar to the coacervation of microencapsulation. If desired, the density of the dispersion system can be modified by altering the specific gravity to make the dispersion hyperbaric or hypobaric. For example, the dispersion material can be made more hyperbaric by the addition of iohexol, iodixanol, metrizamide, sucrose, trehalose, glucose, or other biocompatible molecules with high specific gravity.

One type of dispersion system which can be used according to the invention consists of a dispersion of the therapeutic agent in a polymer matrix. The therapeutic agent is released as the polymeric matrix decomposes, or biodegrades, into soluble products which are excreted from the body. Several classes of synthetic polymers, including polyesters (Pitt, *et al.*, in *Controlled Release of Bioactive Materials*, R. Baker, Ed., Academic Press, New York, 1980); polyamides (Sidman, *et al.*, *Journal of Membrane Science*, 7:227, 1979); polyurethanes (Maser, *et al.*, *Journal of Polymer Science, Polymer Symposium*,

66:259, 1979); polyorthoesters (Heller, *et al.*, *Polymer Engineering Science*, 21:727, 1981); and polyanhydrides (Leong, *et al.*, *Biomaterials*, 7:364, 1986) have been studied for this purpose. Considerable research has been done on the polyesters of PLA and PLA/PGA. Undoubtedly, this is a consequence of convenience and safety considerations. These polymers are readily available, since they have been used as biodegradable sutures, and they decompose into non-toxic lactic and glycolic acids (see, U.S. 4,578,384; U.S. 4,765,973; incorporated by reference).

Solid polymeric dispersion systems can be synthesized using such polymerization methods as bulk polymerization, interfacial polymerization, solution polymerization, and ring opening polymerization (Odian, G., *Principles of Polymerization*, 2nd ed., John Wiley & Sons, New York, 1981). Using any of these methods, a variety of different synthetic polymers having a broad range of mechanical, chemical, and biodegradable properties are obtained; the differences in properties and characteristics are controlled by varying the parameters of reaction temperatures, reactant concentrations, types of solvent, and reaction time. If desired, the solid polymeric dispersion system can be produced initially as a larger mass which is then ground, or otherwise processed, into particles small enough to maintain a dispersion in the appropriate physiologic buffer (see, for example, U.S. 4,452,025; U.S. 4,389,330; U.S. 4,696,258; incorporated by reference).

The mechanism of release of therapeutic agent from biodegradable slabs, cylinders, and spheres has been described by Hopfenberg (in *Controlled Release Polymeric Formulations*, pp. 26-32, Paul, D.R. and Harris, F.W., Eds., American Chemical Society, Washington, D.C., 1976). A simple expression

-9-

describing additive release from these devices where release is controlled primarily by matrix degradation is:

$$M_t/M_\infty = 1 - [1 - k_0 t/C_0 a]^n$$

5 where  $n = 3$  for a sphere,  $n = 2$  for a cylinder, and  $n = 1$  for a slab. The symbol  $a$  represents the radius of a sphere or cylinder or the half-thickness of a slab.  $M_t$  and  $M_\infty$  are the masses of drug release at time  $t$  and at infinity, respectively.

Most preferred as a dispersion system according to the invention are synthetic membrane vesicles. The term "synthetic membrane vesicles" denotes  
10 structures having one or more concentric chambers, commonly known as liposomes, as well as structures having multiple non-concentric chambers bounded by a single bilayer membrane.

When phospholipids are dispersed in aqueous media, they swell, hydrate, and spontaneously form multilamellar concentric bilayer vesicles with layers of  
15 aqueous media separating the lipid bilayer. Such systems are usually referred to as multilamellar liposomes or multilamellar vesicles (MLVs) and have diameters ranging from about 100nm to about 4 $\mu$ m. When MLV's are sonicated, small unilamellar vesicles (SUVs) with diameters in the range of from about 20nm to about 50 nm are formed, which contain an aqueous solution in  
20 the core of the SUV.

The composition of the synthetic membrane vesicle is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used.

-10-

Examples of lipids useful in synthetic membrane vesicle production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and are saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine.

In preparing vesicles containing a therapeutic agent, such variables as the efficiency of drug encapsulation, lability of the drug, homogeneity and size of the resulting population of vesicles, drug-to-lipid ratio, permeability instability of the preparation, and pharmaceutical acceptability of the formulation should be considered. (Szoka, *et al.*, *Annual Reviews of Biophysics and Bioengineering*, 9:467, 1980; Deamer, *et al.*, in *Liposomes*, Marcel Dekker, New York, 1983, 27; Hope, *et al.*, *Chem. Phys. Lipids*, 40:89, 1986).

If desired, it is possible to produce synthetic membrane vesicles with various degrees of target specificity. The targeting of vesicles has been classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be further distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of vesicles to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves the alteration of the vesicle by coupling the vesicle to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the vesicles in order to achieve

-11-

targeting to organs and cell types other than the naturally occurring sites of localization. Alternatively, vesicles may physically localize in capillary beds.

Another dispersion system which can be used according to the invention is resealed erythrocytes. When erythrocytes are suspended in a hypotonic medium, swelling occurs and the cell membrane ruptures. As a consequence, pores are formed with diameters of approximately 200-500 Å which allow equilibration of the intracellular and extracellular environment. If the ionic strength of this surrounding media is then adjusted to isotonic conditions and the cells incubated at 37°C, the pores will close such that the erythrocyte reseals. This technique can be utilized to entrap the therapeutic agent inside the resealed erythrocyte.

The surface of the dispersion system may be modified in a variety of ways. Non-lipid material may be conjugated via a linking group to one or more hydrophobic groups, for example, alkyl chains from about 12-20 carbon atoms. In the case of a synthetic membrane vesicle delivery system, lipid groups can be incorporated into the lipid bilayer in order to maintain the compound in stable association with the membrane bilayer. Various linking groups can then be used for joining the lipid chains to the compound.

Whether a ligand or a receptor, the number of molecules bound to a synthetic membrane vesicle will vary with the size of the vesicle, as well as the size of the molecule to be bound, the binding affinity of the molecule to the target cell receptor or ligand, as the case may be, and the like. In most instances, the bound molecules will be present on the vesicle from about 0.05 to about 2 mol%, preferably from about 0.1 to about 1 mol%, based on the percent of

-12-

bound molecules to the total number of molecules in the outer membrane bilayer of the vesicle.

- In general, the compounds to be bound to the surface of the targeted delivery system will be ligands and receptors which will allow the dispersion system to actively "home in" on the desired tissue. A ligand may be any compound of interest which will specifically bind to another compound, referred to as a receptor, such that the ligand and receptor form a homologous pair. The compounds bound to the service of the dispersion system may vary from small haptens from about 125-200 molecular weight to much larger antigens with molecular weights of at least about 6000, but generally of less than 1 million molecular weight. Proteinaceous ligands and receptors are of particular interest. In general, the surface membrane proteins which bind to specific effector molecules are referred to as receptors. As presently used, however, most receptors will be antibodies. These antibodies may be monoclonal or polyclonal and may be fragments thereof such as Fab, F(ab')<sub>2</sub>, and F<sub>v</sub>, which are capable of binding to an epitopic determinant. Techniques for binding of proteins, such as antibodies, to synthetic membrane vesicles are well known (see, for example, U.S. 4,806,466 and U.S. 4,857,735, incorporated by reference).
- The term "therapeutic agent" as used herein for the compositions of the invention includes, without limitation, drugs, radioisotopes, and immunomodulators. Similar substances are known or can be readily ascertained by one of skill in the art. There may be certain combinations of therapeutic agent with a given type of dispersion system which are more compatible than others. For example, the method for producing a solid polymeric dispersion may not be compatible with the continued biological activity of a proteinaceous

-13-

therapeutic agent. However, since conditions which would produce an incompatible pairing of a particular therapeutic agent with a particular dispersion system are well known, or easily ascertained, it is a matter of routine to avoid such potential problems.

5 The drugs which can be incorporated in the dispersion system include non-proteinaceous as well as proteinaceous drugs. The term "non-proteinaceous drugs" encompasses compounds which are classically referred to as drugs such as, for example, mitomycin C, daunorubicin, vinblastine, AZT, and hormones. Of particular interest are anti-tumor cell-cycle specific drugs such  
10 as cytarabine, methotrexate, 5-fluorouracil (5-FU), floxuridine (FUDR), bleomycin, 6-mercapto-purine, 6-thioguanine, fludarabine phosphate, vincristine, and vinblastine. Similar substances which can also be used according to the invention are within the skill of the art.

The proteinaceous drugs which can be incorporated in the dispersion system  
15 include immunomodulators and other biological response modifiers as well as antibodies. The term "biological response modifiers" encompasses substances which are involved in modifying the immune response in such manner as to enhance the particular desired therapeutic effect, for example, the destruction of tumor cells. Examples of immune response modifiers include such  
20 compounds as lymphokines. Examples of lymphokines include tumor necrosis factor, the interleukins, lymphotoxin, macrophage activating factor, migration inhibition factor, colony stimulating factors and the interferons. Interferons which can be incorporated into the dispersion systems include  $\alpha$ -interferon,  $\beta$ -interferon, and  $\gamma$ -interferon and their subtypes. In addition, peptide or  
25 polysaccharide fragments derived from these proteinaceous drugs, or

-14-

independently, can also be incorporated. Those of skill in the art will know, or can readily ascertain, other substances which can act as proteinaceous drugs.

In using radioisotopes to treat cell proliferative disorders, such as tumors, certain radioisotopes may be more preferable than others depending on such factors, for example, as tumor distribution and mass, as well as isotope stability and emission. Depending on the type of malignancy present some emitters may be preferable to others. In general,  $\alpha$  and  $\beta$  particle-emitting radioisotopes are preferred in immunotherapy. For example, if a patient has solid tumor foci a high energy  $\beta$  emitter capable of penetrating several millimeters of tissue, such as  $^{90}\text{Y}$ , may be preferable. On the other hand, if the malignancy consists of single target cells, as in the case of leukemia, a short range, high energy  $\alpha$  emitter such as  $^{212}\text{Bi}$  may be preferred. Examples of radioisotopes which can be incorporated in the dispersion system for therapeutic purposes are  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{90}\text{Y}$ ,  $^{67}\text{Cu}$ ,  $^{212}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{212}\text{Pb}$ ,  $^{47}\text{Sc}$ ,  $^{109}\text{Pd}$  and  $^{188}\text{Re}$ . Other radioisotopes which can be incorporated are within the skill in the art.

When an antibody is incorporated into the dispersion system, the antibody, whether monoclonal or polyclonal, may be unlabeled or labeled with a therapeutic agent. The term "antibody" or "immunoglobulin" as used herein, includes intact molecules as well as fragments thereof, such as Fab,  $\text{F(ab)}_2$ , and  $\text{F}_v$ , which are capable of binding to an epitopic determinant on a cell proliferative or infectious neurological disorder etiologic agent. When coupled to an antibody, the therapeutic agent can be coupled either directly or indirectly. One example of indirect coupling is by use of a spacer moiety. These spacer moieties, in turn, can be either insoluble or soluble (Diener, *et al.*, *Science*, 231:148, 1986) and can be selected to enable drug release from the antibody molecule at the target site. Examples of therapeutic agents which can



-15-

be coupled to the antibody for immunotherapy are drugs and radioisotopes, as described above, as well as lectins and toxins.

5      Lectins are proteins, usually isolated from plant material, which bind to specific sugar moieties. Many lectins are also able to agglutinate cells and stimulate lymphocytes. However, ricin is a toxic lectin which has been used immunotherapeutically. This is preferably accomplished by binding the alpha-peptide chain of ricin, which is responsible for toxicity, to the antibody molecule to enable site specific delivery of the toxic effect.

10      Toxins are poisonous substances produced by plants, animals, or microorganisms that, in sufficient dose, are often lethal. Diphtheria toxin is a substance produced by *Corynebacterium diphtheria* which can be used therapeutically. This toxin consists of an  $\alpha$  and  $\beta$  subunit which under proper conditions can be separated. The toxic  $\alpha$  component can be bound to an antibody and used for site specific delivery to a target cell for which the antibodies are specific.

15      Other therapeutic agents which can be coupled to the monoclonal antibodies are known, or can be easily ascertained, by those of ordinary skill in the art.

The labeled or unlabeled antibodies can also be used in combination with other therapeutic agents such as those described above. Especially preferred are therapeutic combinations comprising a monoclonal antibody and an immunomodulator or other biological response modifier. Thus, for example, a

20      monoclonal antibody can be used in combination with  $\alpha$ -interferon. This treatment modality enhances monoclonal antibody targeting of carcinomas by increasing the expression of monoclonal antibody reactive antigen by the carcinoma cells (Greiner, *et al.*, *Science*, 235:895, 1987). A dispersion system

25      based on the use of a synthetic membrane vesicle with multiple non-concentric

-16-

chambers is particularly useful with combination therapy, since the non-concentric chambers can be loaded with different therapeutic agents. Those of skill in the art will be able to select from the various biological response modifiers to create a desired effector function which enhances the efficacy of the monoclonal antibody or other therapeutic agent used in combination.

When the monoclonal antibody of the invention is used in combination with various therapeutic agents, such as those described herein, the administration of the monoclonal antibody and the therapeutic agent usually occurs substantially contemporaneously. The term "substantially contemporaneously" means that the monoclonal antibody and the therapeutic agent are administered reasonably close together with respect to time. Usually, it is preferred to administer the therapeutic agent before the monoclonal antibody. For example, the therapeutic agent can be administered 1 to 6 days before the monoclonal antibody. The administration of the therapeutic agent can be daily, or at any other interval, depending upon such factors, for example, as the nature of the neurological disorder, the condition of the patient and half-life of the agent.

The term "therapeutically effective" as it pertains to the compositions of the invention means that the therapeutic agent is present at a concentration sufficient to achieve a particular medical effect for which the therapeutic agent is intended. Examples, without limitation, of desirable medical effects which can be attained are chemotherapy, antibiotic therapy, and regulation of metabolism. Exact dosages will vary depending upon such factors as the particular therapeutic agent and desirable medical effect, as well as patient factors such as age, sex, general condition and the like. Those of skill in the

-17-

art can readily take these factors into account and use them to establish effective therapeutic concentrations without resort to undue experimentation.

The foregoing is meant to illustrate, but not to limit, the scope of the invention.

Indeed, those of ordinary skill in the art can readily envision and produce  
5 further embodiments, based on the teachings herein, without undue experimentation.

-18-

**EXAMPLE 1****PRODUCTION OF DEPO/ARA-C (DTC101)**

This example describes the production of a synthetic membrane vesicle having multiple non-concentric chambers containing ara-C which are bounded by a single bilayer membrane.

5 Dioleoyl lecithin (8.3 g), dipalmitoylphosphatidyl glycerol (1.66 g), cholesterol (6.15 g), and triolein (1.73 g) were mixed with 800 ml of chloroform (the lipid phase) in a 13-liter glass homogenizer vessel fitted with a 2-inch mixing blade. Next, Cytosine arabinoside (33 mg/ml) was dissolved in 0.151 N HCl (at a final  
10 volume of 1.2 liters) and added to the homogenizer vessel. To form a water-in-oil emulsion, the mixing blade was rotated at 8000 rpm for 10 minutes.

Low ionic strength aqueous component comprising free base lysine (40 mM) and glucose (3.2%) was added to the homogenizer to form the chloroform spherules and the mixing blade was rotated at 3500 rpm for 90 seconds. To  
15 remove the chloroform, nitrogen gas was bubbled through the mixture at 62 liters per minute for 30 minutes while the vessel was heated to 35°C. The resulting product was purified and concentrated by diafiltration using polysulfone hollow-fiber with 0.1 $\mu$  pore size and 8 ft<sup>2</sup> surface area.

**EXAMPLE 2****INTRATHECAL AND INTRAVENTRICULAR TREATMENT WITH  
ENCAPSULATED DEPO/ARA-C****A. PATIENTS AND METHODS**

- 5 Twelve patients with a histologically proven diagnosis of cancer and radiological or cytologic evidence of neoplastic meningitis were treated. This human investigation was performed after approval by the UCSD Human Subjects Committee. There was no performance status requirement and prior intra-CSF chemotherapy was allowed. The patients were given 47 total doses of DTC
- 10 101. There were 4 patients with hematological malignancies and 8 with solid tumors (TABLE 1). Concurrent systemic chemotherapy was given to 5 patients.

-20-

**TABLE 1**  
**PATIENT CHARACTERISTICS**

	<b><u>Total Number of Patients</u></b>	12
	Male	7
5	Female	5
	<b><u>Ages (range, years)</u></b>	6-73
	Median	38
	<b><u>Diagnoses</u></b>	
	Chronic myelogenous leukemia in blast crisis	1
10	AIDS-related non-Hodgkin's lymphoma	2
	Multiple myeloma	1
	Breast cancer	2
	Non-small cell lung cancer	1
	Head and neck cancer	1
15	Renal cell tumor	1
	Melanoma	1
	Primitive neuroectodermal tumor	2
	<b><u>Prior Therapy for Meningeal Disease</u></b>	
	With prior therapy	9
20	Without prior therapy	4
	<b><u>Types of Prior Therapy</u></b>	
	Methotrexate	6
	Cytarabine	3
	ThioTEPA	3
25	Interferon	1

-21-

An Ommaya reservoir was placed in the right lateral ventricle in all but one patient with chronic myelogenous leukemia in blast crisis. Therapy consisted of DTC 101 suspended in a preservative-free 0.9% NaCl solution administered intraventricularly or by the lumbar intrathecal route as a single injection once every 2-3 weeks. The reservoir was flushed with autologous CSF after DTC 101 dosing and at each CSF sampling.

## B. TREATMENT

The initial dose of 12.5 mg was escalated (25, 37.5, 50, 75, 125 mg) after at least 3 cycles in 2 patients who were available for evaluation. Treatment was continued until disease progression or to a maximum of 7 doses. Initial work-up included history and physical examination and complete neurological examination; CBC and platelet count; CSF sample for cytology; serum chemistries; CT or MR brain scan with and without appropriate contrast agents and Indium-DTPA CSF flow studies (Chamberlain, *et al.*, *Neurol.*, 40:435-438, 1990; Chamberlain, *et al.*, *Neurol.*, 41:1765-1769, 1991). Before each cycle of DTC 101, complete neurological history and examination, blood counts, and chemistries were done, and CSF samples were obtained for cytologic examination. Complete cytologic response was defined as two consecutive negative CSF cytology examinations at least one week apart; anything less than a complete response was considered as no response. Progressive disease was defined as conversion from negative to positive cytology. Changes in parenchymal CNS lesions or lesions outside the CNS were not used as part of response determination since these were not expected to be influenced by intra-CSF therapy. Treatment-induced toxicities were scored using the "Common Toxicity Scale" of the National Cancer Institute.

-22-

Figure 1 shows the CSF pharmacokinetics of cytarabine following intraventricular administrations of DTC 101 at various doses ranging from 12.5 to 125 mg, where CSF samples were obtained from the same ventricle into which DTC 101 had been injected. Panel A, total cytarabine concentration; panel B, free cytarabine concentration. Each data point is an average from at least three courses and the error bars represent standard errors of mean. Following intraventricular administration of a maximum tolerated dose (75 mg), the ventricular concentration of free cytarabine (cytarabine that had been released from DepoFoam particles into the CSF) decreased biexponentially with an average initial ( $\alpha$ ) half-life of  $9.4 \pm 1.6$  hrs (SEM), and terminal ( $\beta$ ) half-life of  $141 \pm 23$  hrs (SEM). The total ventricular concentration (free plus encapsulated cytarabine) decreased in a similar biexponential manner.

### Pharmacokinetic Studies

Ventricular CSF and blood samples were obtained immediately before injection and at 1 hr and then 1, 2, 4, 7, 14, and 21 days following injection. Lumbar CSF samples were obtained in selected patients as a part of evaluation for lumbar CSF cytology at one of these same time points. For intralumbar injections, a sample from the lumbar sac was obtained 3 minutes after injection in lieu of the 1 hr sample. All CSF and blood samples were collected in tubes containing tetrahydrouridine at a final concentration of  $40 \mu\text{M}$  to prevent *in vitro* catabolism of cytarabine to uracil arabinoside (ara-U) by cytidine deaminase. The heparinized blood samples were immediately placed on ice and plasma was separated from blood cells by centrifugation. The CSF samples were centrifuged at  $600 \times g$  for 5 minutes to separate DepoFoam particles from the free cytarabine fraction (the supernate). The DepoFoam pellet was lysed by vortexing sequentially in  $200 \mu\text{l}$  methanol and in distilled water. The free



-23-

cytarabine fractions of CSF were analyzed without further processing. The plasma was ultrafiltered (YMT membrane, No. 4104; Amicon Corp., Danvers, MA). The CSF and plasma samples were stored frozen at -20° until analysis by a modification of previously described method (Kaplan, JG, *et al.*, *J Neuro-Onc*, 9:225-229, 1990). The samples were analyzed on a high performance liquid chromatography system (Waters Associates, Milford, MA) with 254 and 280 nm UV detectors, two Pecosphere C-18 reverse-phase columns (3X3C Cartridge; Perkin-Elmer, Norwalk, CT) in tandem, and 6.7 mM potassium phosphate/3.3 mM phosphoric acid mixture (pH 2.8) as an isocratic mobile phase at a flow rate of 1.0 ml/min. Retention time for cytarabine was 6 minutes and that for the major metabolite, ara-U, was 7 minutes. There were no interfering peaks.

The pharmacokinetic curves were fit to the biexponential function  $C(t) = Ae^{-\alpha t} + Be^{-\beta t}$ , where  $C(t)$  is the concentration at time  $t$ ,  $A$  and  $B$  are constants and  $\alpha$  and  $\beta$  are the initial and terminal rate constants. The RSTRIP program (MicroMath Scientific Software, Salt Lake City, UT) was used to perform the curve fitting by iterative non-linear regression. The area under the concentration-versus-time curve (AUC) was determined by the linear trapezoidal rule up to the last measured concentration and extrapolated to infinity. CSR clearance of cytarabine was determined by dividing the dose of cytarabine by the AUC. The initial volume of distribution of cytarabine in CSF ( $V_d$ ) was calculated by dividing the dose of cytarabine by the concentration measured at 1 hr.

TABLE 2 shows the detailed pharmacokinetic parameters as a function of dose. The half-lives ( $T_{1/2}$ ), volumes of distribution ( $V_d$ ), and clearances (Cl) did not change significantly as the dose was escalated from 12.5 to 125 mg.

**TABLE 2**  
**PHARMACOKINETIC PARAMETERS AS A FUNCTION OF DOSE**

Dose	12.5 mg	25 mg	37.5 mg	50 mg	75 mg	125 mg
Cycles	3	6	5	6	7	3
<u>Total Cytarabine</u>						
$C_{max}$ ( $\mu\text{g/ml}$ )	161 $\pm$ 35	263 $\pm$ 51	308 $\pm$ 98	468 $\pm$ 112	554 $\pm$ 146	1373 $\pm$ 740
$\alpha$ $T_{1/2}$ (hr)	2.3 $\pm$ 5	8.0 $\pm$ 1.5	6.0 $\pm$ 1.7	5.0 $\pm$ 1.0	7.6 $\pm$ 1.5	8.4 $\pm$ 1.5
$\beta$ $T_{1/2}$ (hr)	47 $\pm$ 22	229 $\pm$ 70	75 $\pm$ 16	87 $\pm$ 15	95 $\pm$ 16	161 $\pm$ 75
AUC ( $\mu\text{g-hr/ml}$ )	2210 $\pm$ 452	5910 $\pm$ 1550	4820 $\pm$ 1230	7390 $\pm$ 1150	9090 $\pm$ 1750	20800 $\pm$ 9400
Cl (ml/min)	.11 $\pm$ .02	.09 $\pm$ .02	.18 $\pm$ .04	.13 $\pm$ .02	.27 $\pm$ .07	.18 $\pm$ .07
$V_d$ (ml)	91 $\pm$ 21	112 $\pm$ 22	206 $\pm$ 64	150 $\pm$ 35	275 $\pm$ 95	286 $\pm$ 154
<u>Free Cytarabine</u>						
$C_{max}$ ( $\mu\text{g/ml}$ )	25 $\pm$ 12	77 $\pm$ 17	55 $\pm$ 12	73 $\pm$ 11	66 $\pm$ 31	282 $\pm$ 111
$\alpha$ $T_{1/2}$ (hr)	5.5 $\pm$ 7	7.6 $\pm$ 1.6	4.6 $\pm$ 1.4	5.5 $\pm$ 1.4	9.4 $\pm$ 1.6	7.3 $\pm$ .1
$\beta$ $T_{1/2}$ (hr)	71 $\pm$ 13	123 $\pm$ 22	112 $\pm$ 31	80 $\pm$ 18	141 $\pm$ 23	129 $\pm$ 46
AUC ( $\mu\text{g-hr/ml}$ )	355 $\pm$ 151	$\pm$ 1595 $\pm$ 234	853 $\pm$ 210	1327 $\pm$ 135	1343 $\pm$ 465	4525 $\pm$ 1775
Cl (ml/min)	1.2 $\pm$ .6	.30 $\pm$ .1	1.1 $\pm$ .3	.66 $\pm$ .06	1.7 $\pm$ .4	.73 $\pm$ .25

Abbreviations:  $C_{max}$ , maximum concentration;  $\alpha$   $T_{1/2}$ , initial half-life;  $\beta$   $T_{1/2}$ , terminal half-life; AUC, area under the curve; Cl, clearance;  $V_d$ , volume of distribution

Figure 2 depicts the maximum ventricular cytarabine concentration (Panel A) measured at 1 hr following DTC 101 administration, and the CSF drug exposure (AUC, Panel B) as a function of dose administered intraventricularly. Open and closed circles represent total and free cytarabine, respectively. Each data point is an average from at least three courses and the error bars represent standard errors of mean. There was a linear relationship between these pharmacokinetic parameters and dose, indicating that there was no saturation of clearance process over the dose range examined. The total ara-U AUC averaged  $3.7 \pm 0.9\%$  (SEM) of the total cytarabine AUC in the CSF. No cytarabine or ara-U was detected in the plasma (detection limit =  $0.25 \mu\text{g/ml}$  for both) at any time point.

Lumbar CSF samples were obtained during five courses in two patients following intraventricular administration of DTC 101 at the maximum tolerated dose (75 mg). Figure 3 compares the ventricular drug concentration and DTC 101 particle count with that in the lumbar subarachnoid space. Comparison of the ventricular (closed circles) and lumbar (open circles) cytarabine concentrations (total and free, Panels A and B, respectively) and DTC 101 particle count (Panel C) as functions of time following intraventricular administration of DTC 101. The initial ventricular free cytarabine concentration decreased in an exponential fashion with a half-life of 6.8 hrs; cytarabine became detectable in lumbar CSF at 1.25 hrs and then increased rapidly with a doubling time of 0.53 hrs. Subsequently, the lumbar and ventricular concentrations of free and total cytarabine decreased in parallel fashion, with the lumbar drug concentrations remaining comparable to those in the ventricle throughout the terminal phase of the decay curve.

-26-

Both ventricular and intralumbar CSF samples were obtained from four patients given DTC 101 intrathecally by lumbar puncture. Figure 4 shows that a therapeutic concentration of free cytarabine ( $>0.1 \mu\text{g/ml}$ ) was maintained for 3 to 6 days in ventricular CSF following intrathecal lumbar injection, and a significant concentration of total cytarabine was found in the ventricular CSF for 14 days following intralumbar administration. Cytarabine concentration in the ventricular CSF as a function of time (solid lines), and lumbar CSF cytarabine concentration at 3 minutes and 14-days (broken lines), following intralumbar administration of DTC 101. Open squares and circles represent total cytarabine concentrations and closed squares and circles represent free cytarabine concentrations. A therapeutic concentration of free cytarabine was maintained for more than 14 days in the lumbar subarachnoid space following intralumbar injection.

TABLE 3 summarizes the toxicities of DTC 101 as a function of dose. The toxicities were transient and in no instance did drug-related toxicity delay therapy with a subsequent dose of DTC 101. There was one death due to the occurrence of a toxic encephalopathy that developed 36 hours following intraventricular administration of 125 mg of DTC 101. This patient was also receiving concurrent whole brain irradiation (20 Gy in 5 fractions) for partial blockage of CSF flow at the base of brain. There were no hematological toxicities attributable to DTC 101 except in one patient who had an autologous bone-marrow transplant two months prior to DTC 101 administration. The maximum tolerated dose of DTC 101 was 75 mg; dose limiting toxicity occurred a dose of 125 mg, at which there was excessive vomiting and encephalopathy (TABLE 3).

-27-

**TABLE 3****TOXICITY OF DTC 101 AS A FUNCTION OF DOSE**

Dose (mg)		12.5	25	37.5	50	75	125
Patients		2	6	5	4	8	4
5	Courses	3	7	7	6	20	4
Fever		1 (1)*	0 (4)	0 (1)	0 (3)	0 (5)	0 (1)
Headache		0 (1)	0 (7)	0 (2)	2 (2)	0 (4)	1 (2)
Neck/back pain		0 (0)	0 (0)	0 (0)	0 (1)	0 (3)	0 (0)
Nausea/vomiting		0 (3)	1 (2)	1 (3)	0 (4)	2 (4)	3 (1)
10	Cerebellar	0 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Tinnitus		0 (0)	0 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Encephalopathy		0 (0)	1 (1)	0 (0)	1 (0)	0 (0)	1 (1)
Hyponatremia		0 (0)	0 (0)	0 (0)	0 (0)	0 (1)	0 (0)

\* The numbers in the columns represent toxicities greater than grade 2.

15 The numbers in parenthesis represent toxicities of grade 1 or 2.

TABLE 4 shows that oral dexamethasone in doses of 2 to 4 mg twice per day had a major effect on blunting toxicities associated with DTC 101. Fever, headache, and nausea/vomiting were all reduced. There were three patients who received the same dose of DTC 101 with and without oral dexamethasone.

-28-

All three patients manifested toxicity without dexamethasone and in each patient the toxicity was almost completely suppressed with concurrent oral dexamethasone.

**TABLE 4**

5                    **EFFECT OF CONCURRENT ORAL DEXAMETHASONE**  
                       **ADMINISTRATION ON DTC 101 TOXICITY**

		<u>(-) Dexamethasone</u>		<u>(+) Dexamethasone</u>	
		<u>9</u>		<u>12</u>	
		<u>1-2</u>	<u>3-4</u>	<u>1-2</u>	<u>3-4</u>
10	Number of courses				
	% with toxicity grade				
	Fever	44	0	8	0
	Headache	44	0	8	0
	Back/neck pain	33	0	0	0
	Nausea/vomiting	22	22	17	8
15	Encephalopathy	0	0	0	0

---

Intraventricular and intralumbar routes were combined.

Four patients were treated with DTC 101 by the lumbar intrathecal route. The toxicities were similar to those observed following intraventricular administration except 4 of 9 cycles were associated with grade 1 to 2 low back pain.

-29-

Nine of 12 patients had a positive CSF cytology immediately prior to treatment. Seven of these 9 cytologically evaluable patients cleared their CSF of malignant cells with DTC 101 treatment (TABLE 5). The duration of response ranged from 2 to 26 weeks with a median of 16 weeks. One non-responding patient  
5 had an AIDS-related non-Hodgkin's lymphoma and the other had a primary brain tumor. Survival time for all patients on study ranged from 3 to 64 weeks (median: 21 weeks).

**TABLE 5****CSF CYTOLOGIC RESPONSE TO DTC 101**

	Number of Patients	12
	Number with positive CSF cytology	9
5	Cleared CSF with DTC 101	7

**Responders**

	Breast cancer	1
	Non-small cell lung cancer	1
	Multiple Myeloma	1
10	CML in blast crisis	1
	Melanoma	1
	AIDS-related non-Hodgkin's lymphoma	1
	Primitive neuroectodermal tumor	1

**Non-Responders**

15	AIDS-related NHL	1
	Primitive neuroectodermal tumor	1

Three of twelve patients had evidence of neoplastic meningitis by CT or MRI scan, but had negative CSF cytology prior to therapy and were not evaluable for cytologic response. However, none of these three patients developed a positive CSF cytology while on treatment.



-31-

Surprisingly, responses were observed at all dose levels and were not limited to the higher doses. One patient with multiple myeloma relapsed following an initial cytologic response at the 25 mg dose level, then responded again to a higher dose (37.5 mg) of DTC 101. Three of five patients presenting with  
5      headache responded clinically to DTC 101 therapy. No clinical improvement was observed in patients with focal (ophthalmoplegia or paraparesis) or diffuse (acute confusional state) neurologic deficits at the start of therapy.

A number of embodiments of the present invention have been described. Nevertheless, it will be understood that various modifications may be made  
10      without departing from the spirit and scope of the invention. Accordingly, it is to be understood that the invention is not to be limited by the specific illustrated embodiment, but only by the scope of the appended claims.

**CLAIMS**

1. A method for ameliorating a neurological disorder which comprises administering to the cerebrospinal fluid (CSF) of a human with the disorder a therapeutically effective amount of a therapeutic agent in a dispersion system such that the agent persists in the cerebro-ventricular space for a time sufficient to ameliorate the disorder.
2. The method of claim 1, wherein the neurological disorder is a cell proliferative disease.
3. The method of claim 2, wherein the cell proliferative disease is a benign tumor.
4. The method of claim 2, wherein the cell proliferative disorder is a malignant tumor.
5. The method of claim 4, wherein the malignant tumor is a primary tumor.
6. The method of claim 4, wherein the malignant tumor is a metastatic tumor.
7. The method of claim 6, wherein the metastatic tumor is neoplastic meningitis.
8. The method of claim 1, wherein the neurological disorder is an infectious disease.
9. The method of claim 8, wherein the infectious disease is caused by a virus.

10. The method of claim 9, wherein the virus is a slow virus.
11. The method of claim 9, wherein the virus is a retrovirus.
12. The method of claim 9, wherein the retrovirus is a *Lentivirus*.
13. The method of claim 12, wherein the *Lentivirus* is selected from the group consisting of HTLV-I, HTLV-II, HIV-1, and HIV-2.
14. The method of claim 8, wherein the infectious disease is caused by a prokaryote.
15. The method of claim 14, wherein the prokaryote is a bacteria.
16. The method of claim 15, wherein the bacteria is selected from the group consisting of *Hemophilus influenzae*, *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella-Enterobacter*, *Proteus spp.*, *Mycobacterium tuberculosis*, *Staphylococcus aureus*, and *Listeria monocytogenes*.
17. The method of claim 8, wherein the infectious disease is caused by a eukaryote.
18. The method of claim 17, wherein the eukaryote is a fungus.
19. The method of claim 18, wherein the fungus is selected from the group consisting of *Cryptococcus*, *Coccidioides immitis*, *Histoplasma*, *Candida*, *Nocardia*, and *Blastomyces*.

20. The method of claim 1, wherein the neurological disorder is metabolically caused by a metabolic dysfunction.
21. The method of claim 20, wherein the metabolic dysfunction is an autoimmune disease.
22. The method of claim 1, wherein the therapeutic agent is selected from the group consisting of an anti-tumor drug, an anti-bacterial drug, and an anti-viral drug.
23. The method of claim 22, wherein the anti-tumor drug is a cell-cycle phase specific drug.
24. The method of claim 23, wherein the anti-tumor drug is specific for the S phase of the cell cycle.
25. The method of claim 24, wherein the drug is cytarabine.
26. The method of claim 1, wherein the dispersion system is a synthetic membrane vesicle.
27. The method of claim 26, wherein the synthetic membrane vesicle is a liposome.
28. The method of claim 27, wherein the liposome contains multiple concentric chambers.

29. The method of claim 26, wherein the synthetic membrane vesicle contains multiple non-concentric chambers.
30. The method of claim 1, wherein dispersion system is a polymeric matrix.
31. The method of claim 1, wherein the dispersion system is hyperbaric relative to CSF.
32. The method of claim 31, wherein the dispersion is hyperbaric by encapsulation of molecules with higher specific gravity than CSF.
33. The method of claim 32, wherein the molecules with higher specific gravity are iodinated.
34. The method of claim 33, wherein the iodinated molecules are selected from the group consisting of iohexol, iodixanol, and metrizamide.
35. The method of claim 32, wherein the molecules with higher specific gravity are carbohydrates.
36. The method of claim 35, wherein the carbohydrates are selected from the group consisting of sucrose, trehalose, and glucose.
37. The method of claim 1, wherein the dispersion system is hypobaric relative to CSF.
38. The method of claim 1, wherein the dispersion system is target specific.

-36-

39. The method of claim 38, wherein the dispersion is anatomically targeted.
40. The method of claim 38, wherein the dispersion is mechanistically targeted.
41. The method of claim 40, wherein the mechanistic targeting is passive.
42. The method of claim 40, wherein the mechanistic targeting is active.
43. The method of claim 42, wherein the dispersion system is actively targeted by coupling with a moiety selected from the group consisting of a sugar, a glycolipid and a protein.
44. The method of claim 43, wherein the protein is an antibody.
45. The method of claim 1, wherein the dispersion system is administered intraventricularly.
46. The method of claim 1, wherein the dispersion system is administered intralumbar.
47. The method of claim 46, wherein the intralumbar administration is administered once.




FIG. 1A

2/5




FIG.1B



3/5






FIGURE 2

4/5

FIGURE 3






FIGURE 4

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :A61K 9/127

US CL :424/450

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/450, 422, 486; 514/49

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS: Cerebrospinal (3A) (Admins? or inject?); lipsome?; cytarabine

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,813,399 (GORDON) 21 MARCH 1989 See Abstract; column 4, line 22 and claims.	1-47
Y	US, A, 5,208,021 (JOHNSON) 04 MAY 1993 See Abstract.	2-7
Y	US, A, 4,619,913 (LUCK) 28 OCTOBER 1986 See Abstract, column 3, lines 40 through column 4, line 5.	1-47

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be part of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"Z"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 27 SEPTEMBER 1993	Date of mailing of the international search report 10 DEC. 1993
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer G. S. KISHORE Telephone No. (703) 308-2351